Caas Capital Management LP Halozyme Therapeutics, Inc. Transaction History
Caas Capital Management LP
- $895 Million
- Q1 2025
A detailed history of Caas Capital Management LP transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Caas Capital Management LP holds 4,700 shares of HALO stock, worth $254,834. This represents 0.03% of its overall portfolio holdings.
Number of Shares
4,700Holding current value
$254,834% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding HALO
# of Institutions
597Shares Held
124MCall Options Held
320KPut Options Held
113K-
Black Rock Inc. New York, NY17.6MShares$955 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$696 Million0.02% of portfolio
-
State Street Corp Boston, MA6.05MShares$328 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA3.89MShares$211 Million0.05% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.67MShares$199 Million5.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.55B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...